Introduction
Aggressive pituitary tumors and carcinomas have to date shown persistent resistance to hormonal therapy with dopamine agonists or somatostatin analogs and as such represent a therapeutic challenge (1) . While conventional chemotherapies are largely ineffective (2, 3) , recent case reports using temozolomide, an oral alkylating agent used in the management of glioblastoma, have given some hope, especially at early stages (4) (5) (6) . However, about 60% of the published cases demonstrated only an initial response to temozolomide therapy (5, 7) with up to 25% of these patients becoming resistant to temozolomide during follow-up (5, (7) (8) (9) . Since temozolomide treatment is not effective for all pituitary carcinomas or aggressive tumors, the development of new therapeutic options is necessary.
The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is constitutively activated in human tumors (10) and is a key regulator of tumor cell growth, proliferation and apoptosis. This pathway is overexpressed and/or activated in pituitary tumors (11, 12) suggesting that pituitary adenomas would be sensitive to treatment with mTOR inhibitors. Treatment with the allosteric mTOR inhibitor everolimus decreased viability among pituitary tumor cell lines (13) and primary cell cultures of human nonfunctioning pituitary tumors (14) , indicating mTOR inhibition as a promising antiproliferative therapeutic option for aggressive pituitary tumors. However, mTOR inhibitors fail to induce a response in most human pituitary tumors in vitro (15) and to date have had no successful application in clinical practice (16) .
Resistance to the mTOR inhibitor rapamycin is in part attributed to elimination of the negative feedback loop of the mTOR target p70 S6K onto the PI3K pathway. In an attempt to bypass this resistance by an upstream blockade of the PI3K pathway (17), PI3K inhibitors and dual PI3K/mTOR inhibitors were developed with favorable safety profiles (18, 19) . The dual PI3K/mTOR inhibitor NVP-BEZ235 has induced G1/S cell cycle arrest and apoptosis in neuroendocrine tumor cell lines of various origins (20) , reduced viability and activated apoptosis among human bronchial carcinoid tumor cells in vitro (21) , and inhibited cell viability of a rat model of pituitary adenomas in vitro (22) . In xenograft models, the pan-Class I PI3K inhibitor NVP-BKM120 (Buparlisib) has demonstrated dose-dependent inhibition of tumor growth in vivo (19) .
The aim of our present study was to investigate the potential use of PI3K/Akt/mTOR pathway inhibitors in the treatment of aggressive pituitary tumors. We chose PRL-secreting pituitary tumors as our test model, since while most of these tumors are easily managed with dopamine agonists, those that acquire resistance constitute a large portion of all aggressive pituitary tumors and carcinomas with a poor prognosis (5, 23) . We compared the effects of the pure PI3K inhibitor NVP-BKM120 with those of the dual PI3K/mTOR inhibitor NVP-BEZ235 both in vitro on somatolactotroph pituitary tumor GH3 cells and in vivo on a rat model of PRL pituitary tumor, SMtTW-3 (24, 25) .
Material and Methods

Reagents
NVP-BEZ235 and NVP-BKM120 (Buparlisib) were kindly provided by Novartis Pharma, Switzerland. Compounds were dissolved in DMSO (Sigma-Aldrich) for in vitro studies. NVP-BEZ235 was prepared in a 5% (w/v) methylcellulose solution (Colorcon), and NVP-BKM120 in the same solution with 0.5% (v/v) tween80 as vehicle for in vivo studies.
The cell counting kit assay (CCK-8) was purchased from Sigma. The Cycle Test Plus DNA reagent kit and FITC Annexin V Apoptosis detection kit were purchased from BD Biosciences. Primary antibodies against mTOR and p-mTOR (Ser2448) (Millipore); Akt, pAkt-Ser473, S6, p-S6-Ser235/236, p-Rb-Ser780, PARP, cleaved PARP (cl-PARP), cleaved caspase-3 (cl-caspase-3), p-p44/42 MAPK (Thr202/Tyr204), p44/42 MAPK, PTEN and β-actin were made in rabbit (Cell Signaling Technology). Primary antibodies against cyclin D3, Cdk4 (Cell Signaling Technology), cyclin E (Santa Cruz Biotech) and Cdk2 (BD Transduction laboratories) were made in mouse. Anti-mouse and anti-rabbit HRP-conjugated secondary antibodies were used (purchased from Cell Signaling Technology. 
SMtTW tumor model
The rats used in the experiments were 2-month-old female Wistar/Furth WF/Ico inbred strain (Charles River laboratories). All rats were treated according to guidelines meeting French Ethics Committee approval (agreement n°BH2011-37).
The SMtTW lineage used was one of four generated in our laboratory since 1985 from spontaneous pituitary tumors of Wistar/Furth rats. The main characteristics of the strains produced and the grafting procedure for their generation have previously been described in detail (25) . Briefly, from each spontaneous tumor, a thin piece (2x2mm) was slipped under the kidney capsule of female consanguineous rats (heterotopic and allogenic graft) and produced a tumor. Each lineage was maintained by serial grafts provided from these tumors growing under the kidney capsule. In this study, we used the SMtTW3 tumor lineage that presented a PRL phenotype with high plasma PRL levels (1-150 μg/ml) and a low secretion of GH (0.4μg/ml) that grows rapidly, is invasive and sometimes necrotic and metastatic, and shares common characteristics and gene expression profile with the human aggressive prolactinomas (23, 25) .
Four weeks after grafting, tumor-bearing rats were divided into two groups of comparable tumor size distribution before being administered via oral gavage five days a week, a vehicle (control) or one of either the PI3K inhibitor NVP-BKM120 or the dual PI3K/mTOR NVP-BEZ235. NVP-BEZ235 was administered at 20mg/kg/d for 3 (control n=10, NVP-BEZ235 n= 13) or 6 weeks (control n=9, NVP-BEZ235 n= 13). NVP-BKM120 was administered at a reduced dose of 5mg/kg/d (n=12) for 4 weeks only and compared to control (n=8). This reduced dose and duration was due to poor tolerance and hyperglycemia induced by high doses initially tested. Animal weight, blood glucose (Freestyle ® blood glucose monitor, Abbott Diabetes Care) and plasma PRL levels were regularly measured during treatment and at autopsy. Tumors were removed, separated from kidney tissue, measured, weighed and prepared immediately according to different analytical techniques.
Cell viability
The effect of NVP-BEZ235 and NVP-BKM120 on cell viability was established using the CCK-8 assay according to the procedure recommended by the supplier. Cells were plated in 96-well plates at a concentration of 5x10 4 cells per 100 µL of medium/well, incubated for 24h with each drug at 1, 10, 100 and 250 nM. Controls were performed in DMSO with the same dilutions. Absorbance was measured at 450 nm using a multiplate reader (Multiskan Ex, ThermoFisher). Three replicate wells were used for each analysis, and at least three independent experiments were conducted.
Flow cytometry
After 24h of treatment, all cells were collected and assigned to different analytical reproducibility. All data concerning viability and apoptosis were analyzed using the DIVA software, and those relating to the cell cycle were evaluated using the ModFit software.
Western Blot
Pelleted GH3 cells or tumor fragments were extracted by sonication in lysis buffer complemented with phosphatase and protease inhibitors (Roche Diagnostics) (26) . Protein concentrations were assessed by fluorometry using the Quant-iT Assay kit (Life Technologies). SDS-PAGE electrophoresis (Criterion XT Precast Gel, 4-12% Bis-Tris, BioRad Laboratories) was then performed using 15 µg of total proteins for GH3 cells and 12 µg for tumors before transfer to a nitrocellulose membrane (Protan 0.45, Whatman, ThermoFisher). After blocking with TBS-T BSA5% (w/v), membranes were incubated with specific primary antibodies (overnight), before their incubation for 1 hour with secondary antibodies. Detection was achieved using an enhanced chemiluminescence system (Immobilon Western, Millipore). Densitometric quantification of the immunoblot bands was performed using ImageJ software.
Mitosis
For light microscopy, tumor fragments were fixed in Bouin-Hollande, embedded in paraffin, cut into 5-µm sections and stained with hematoxylin-eosin. For mitotic index, mitotic cells were counted at 400 × magnification in ten representative fields per tumor, with an average count of 5000 nuclei.
Human prolactinomas in primary cell culture
This study was approved by the Max-Planck-Institute ethics committee and informed consent was received from each patient or from their relatives. Seven prolactinomas were included. The tumors were removed by transphenoidal surgery and a diagnosis was reached according to clinical, biochemical, radiological and surgical findings. Post-surgical specimens were prepared as previously described (15) . Cell viability, as determined by acridine orange and ethidium bromide staining, was considered acceptable above 80%. Cells were seeded in 96-well plates (10,000 cells per well) and were left for 48 hours before the 24 hour treatment.
Cell proliferation was assessed using the non-radioactive colorimetric WST-1 assay (Roche Molecular Biochemicals) according to the manufacturer's instructions. Cells treated with DMSO alone (in which NVP-BEZ235 and NVP-BKM120 were dissolved) were used as a control. All treatments were carried out in quadruplicate.
Serum PRL assay
Before and after 3-and 6-week treatments with control or NVP-BEZ235 (20mg/ kg), or after a 4-week treatment with control or NVP-BKM120 (5 mg/kg), blood was drawn from the retroorbital sinus or collected at autopsy (24) . Serum was collected for the hormone assay and PRL concentrations were measured by double antibody radioimmunoassay with the reagents purchased at the National Institute of Diabetes and Digestive and Kidney Diseases (PRL rat reagents NIDDK). The intra-assay variability was less than 10%, and the inter-assay variability was less than 12%. Results are expressed as the mean ± SD.
Human PRL was determined using a radioimmunoassay from DPC Biermann, according to the manufacturer's instructions. PRL values were divided by the cell viability values and data are given in [ng/ml]/OD450nm.
Statistical analysis
Statistical analysis was performed with GraphPad Prism 5 software. The nonparametric Mann-Whitney U Test was used to compare two groups (DMSO or control vs. treated). In vitro data were assessed at least three times in triplicate. A p≤0.05 was considered to be statistically significant.
Results
Effects of NVP-BEZ235 and NVP-BKM120 on GH3 cells in vitro
In GH3 cells, treatment with either NVP-BEZ235 or NVP-BKM120 (1, 10, 100 and 250 nM) for 24 h dose-dependently reduced cell viability, reaching statistical significance for NVP-BEZ235 only. NVP-BEZ235 had a stronger inhibitory effect on cell viability compared to NVP-BKM120 (50 % vs. 23 % decrease, respectively, compared to control, P<0.05) (Fig.   1A ), using the CCK8 assay. This difference was less prominent (17 % and 11 % reduction for 250 nM NVP-BEZ235 and NVP-BKM120, respectively; P<0.01 for NVP-BEZ235) using the propidium iodide staining test (Fig. 1B) .
NVP-BEZ235 at concentrations of 10 to 250 nM dose-dependently induced an accumulation of GH3 cells in the G0-G1 phase, alongside a 35% decrease of those in Sphase (P<0.01 vs. DMSO). NVP-BKM120 treatment on the other hand had limited effect on the cell cycle (Fig. 1C) . This differential effect on the cell cycle was reflected by a reduction in Rb phosphorylation observed only after NVP-BEZ235 treatment at concentrations of 1, 100 and 250 nM; NVP-BKM120 had no effect (Fig. 1D) .
Western blot for cell cycle proteins involved in G1/S revealed a strong reduction in Cdk2 and cyclin E protein levels in the NVP-BEZ235-treated GH3 cells (10-250 nM) (Fig.   1E ). NVP-BEZ235 treatment also decreased Cdk4 and cyclin D3 protein levels, though only at the high nanomolar range (100-250 nM) with no effect at lower doses. In contrast, NVP-BKM120 had no effect on Cdk4, cyclin D3 or Cdk2 levels, although it did suppress cyclin E (Fig. 1E ).
NVP-BEZ235 at 100-250 nM induced a significant and dose-dependent increase in apoptosis, as shown by an increase both in cleaved caspase-3 (P<0.01) ( Fig. 2A-B ) and in annexin V (P<0.01) (Fig. 2C) , both hallmarks of apoptosis. Furthermore, as shown in Fig. 2D , NVP-BEZ235 treatment increased cleaved PARP levels. NVP-BKM120 on the other hand had no significant effect on annexin V, cleaved caspase-3 or cleaved PARP (Fig. 2) .
Concerning the PI3K/Akt/mTOR pathway, NVP-BEZ235 treatment reduced levels of Akt and pS6 phosphorylation as well as mTOR phosphorylation at Ser2448 (mediated by p70 S6K) (27) in a dose-dependent manner (Fig. 2E) . While NVP-BKM120 decreased Akt 
phosphorylation, it had no effect on pS6 phosphorylation and mTOR. Neither treatment affected total protein level at any dose.
Effect of NVP-BEZ235 and NVP-BKM120 on SMtTW3 tumors in vivo
At the doses used, neither inhibitor affected rat survival. However, while the growth curve of the NVP-BEZ235 group of rats was similar to that of the control group (243 g vs.
262
.4 g at 6 weeks) (Fig. S1A-B) , the NVP-BKM120 group showed a reduction in body weight after 4 weeks of treatment (183.7 g vs. 238.7 g, P<0.001) (Fig. S2A) . Moreover, blood glucose concentrations transiently increased after initiation of NVP-BKM120 treatment and then normalized for the remaining 4 weeks (132.833 mg/dl vs. 73.375 mg/dl, NS) (Fig. S2B) .
In vivo, NVP-BEZ235 treatment showed a weak inhibitory effect on tumor growth that reached statistical significance after 6 weeks (10.1 ± 1.3 g vs. 11.8 ± 1.8 g at 3 weeks and 36.6 ± 5 g vs. 49.4 ± 3.9, at 6 weeks P<0.05) (Fig. 3A) . In contrast, NVP-BKM120 treatment induced a strong reduction of tumor weight relative to the control group (5.4 ± 0.5 g vs 30.6 ± 1.9 g, P<0.001) after 4 weeks of treatment, at which point the treatment was terminated in view of the endpoint having been reached (Fig. 3B) . This reduction was accompanied by significantly reduced PRL levels in the NVP-BKM120-treated group compared to the control group (2007 ± 231 µg/l vs. 5666 ± 1141 µg/l, P<0.001) at 4 weeks (Fig. 3D) . In contrast, PRL concentrations remained similar between the NVP-BEZ235 group and control group after 3 and 6 weeks of treatment (17530 ± 3600 µg/l vs. 23850 ±6438 µg/l at 3 weeks and 33900 ± 12780 µg/l vs. 31760 ± 14090 µg/l at 6 weeks) (Fig. 3C) .
While both treatments significantly reduced the tumor mitotic index compared to controls (NVP-BEZ235: 37 ± 3 vs. 106 ± 13, P<0.001; Fig. 4A and for NVP-BKM120: 29 ± 6 vs. 58 ± 7, P<0.05; Fig. 4B ), this effect was only transient with NVP-BEZ235. Indeed, the significant effect of NVP-BEZ235 was lost after 6 weeks (43 ± 7 vs. 58 ± 12). Moreover, while both treatments significantly increased cleaved PARP levels, an indicator of apoptosis, NVP- (P<0.05). This NVP-BEZ235-induced effect had lost its significance after 6 weeks, while NVP-BKM120 remained potent throughout the treatment period (P<0.05) (Fig. 4C-D) .
Western blot analysis revealed increased phosphorylated Akt-Ser473 levels in the tumors derived from the NVP-BEZ235-treated rats (6 weeks, P<0.01), while phosphorylated S6 remained unchanged or was slightly increased in some cases (Fig. 5A-B) . In contrast, phosphorylated Akt-Ser473 levels were reduced in most NVP-BKM120-treated tumors (P<0.01; Fig. 5C-D) .
These data show that the initial efficacy of the dual PI3K/mTOR inhibitor NVP-BEZ235 was lost during treatment, an effect that was accompanied by an inability to decrease Akt and S6 phosphorylation. In contrast, the single PI3K inhibitor suppressed Akt phosphorylation and displayed rapid and effective antitumor efficacy.
Effects of NVP-BEZ235 and NVP-BKM120 on primary cell cultures of human PRL tumors
To test the efficacy of the two inhibitors in human pituitary tumors, we used primary cell cultures of PRL-secreting pituitary tumors. NVP-BEZ235 treatment at both 10 and 100 nM significantly decreased PRL secretion (% suppression 37±6 and59±8.7 , respectively, P<0.001; Fig. 6A ) in seven human prolactinomas. In contrast, NVP-BKM120 was effective at the 100 nM concentration only (33±23, P<0.05). Regarding cell viability, only 100 nM NVP-BEZ235 led to a reduction (%suppression 38±12, P<0.05) with the lower doses having no significant effect and NVP-BKM120 remaining ineffective within this nanomolar range (Fig.   6B ).
Discussion
Since the recent reclassification of endocrine pituitary tumors (28, 29 )not all of these tumors are considered as benign. Indeed, around 10% of them are aggressive and suspected of malignancy, and some progress to carcinomas with metastases. (32): the first examined the effect on tumor growth of a combined treatment consisting of nelfinavir and radiation (34) , while the second investigated the combination of temozolomide and XL765 (dual PI3K/mTOR inhibitor) (35) . The development of robust xenograft models must ideally consider the tissue-specific microenvironment of the tumor entities they intend to emulate. In the case of the pituitary gland, consideration of its dense vascular network is critical, as these vessels can be compressed during the development of a tumor mass, ultimately providing an escape mechanism from the inhibitory control of the hypothalamus (36) . In this respect, the kidney microenvironment in which our 
